<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01678924</url>
  </required_header>
  <id_info>
    <org_study_id>214868-007</org_study_id>
    <secondary_id>2012-002240-24</secondary_id>
    <nct_id>NCT01678924</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of AGN-214868 in patients with postherpetic neuralgia
      (PHN).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Average Pain Intensity Score</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Average Pain Intensity Score Responders</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Maximal Area of Spontaneous Pain</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Area of Allodynia</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Evoked Pain Score in the Area of Allodynia</measure>
    <time_frame>Baseline, 12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">282</enrollment>
  <condition>Neuralgia, Postherpetic</condition>
  <arm_group>
    <arm_group_label>AGN-214868 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-214868 Dose 1 given as injections into the area of pain on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-214868 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-214868 Dose 2 given as injections into the area of pain on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-214868 Placebo (Vehicle)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AGN-214868 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGN-214868 Dose 3 given as injections into the area of pain on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-214868</intervention_name>
    <description>AGN-214868 given as injections into the area of pain on Day 1.</description>
    <arm_group_label>AGN-214868 Dose 1</arm_group_label>
    <arm_group_label>AGN-214868 Dose 2</arm_group_label>
    <arm_group_label>AGN-214868 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGN-214868 Placebo (Vehicle)</intervention_name>
    <description>AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.</description>
    <arm_group_label>AGN-214868 Placebo (Vehicle)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postherpetic neuralgia with pain present for at least 9 months

        Exclusion Criteria:

          -  Active herpes zoster skin rash

          -  Anticipated treatment for postherpetic neuralgia during the first 3 months of the
             study, including oral and topical medications, acupuncture, spinal cord stimulation,
             transcutaneous nerve stimulation (TNS), or trigger point injection

          -  Anticipated treatment with pain medication for the treatment of postherpetic neuralgia
             during the first 3 months of the study

          -  Use of capsaicin treatment for postherpetic neuralgia within 6 months, or anticipated
             use during the first 3 months of the study

          -  Use of botulinum toxin of any serotype for any reason within 6 months, or anticipated
             use during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2012</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>August 2, 2016</submitted>
    <returned>September 20, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

